DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

Diabetologia

Volumn 61, Issue 1, 2018, Pages 58-65

  Pieber, Thomas R ^a   Marso, Steven P ^b   McGuire, Darren K ^c   Zinman, Bernard ^d   Poulter, Neil R ^e   Emerson, Scott S ^f   Pratley, Richard E ^g,h   Woo, Vincent ⁱ   Heller, Simon ^j   Lange, Martin ^k   Brown Frandsen, Kirstine ^k   Moses, Alan ^k   Barner Lekdorf, Jesper ^k   Lehmann, Lucine ^k   Kvist, Kajsa ^k   Buse, John B ^l  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Research Medical Center Brookside Campus   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF WASHINGTON   (United States)

^g FLORIDA HOSPITAL   (United States)

^h BURNHAM INSTITUTE   (United States)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k NOVO NORDISK A S   (Denmark)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Hypoglycaemia; Insulin therapy; Macrovascular disease

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ADULT; ALL CAUSE MORTALITY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS; FEMALE; MALE; METABOLISM; MORTALITY;

DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE;

EID: 85029473387     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4422-0     Document Type: Article

References (41)

1. Dailey G (2011) Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther 13(Suppl. 1):S65–S74
2. Lung TW, Petrie D, Herman WH et al (2014) Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. Diabetes Care 37:2974–2981
3. Paty BW (2015) The role of hypoglycemia in cardiovascular outcomes in diabetes. Can J Diabetes 39(Suppl. 5):S155–S159
4. Snell-Bergeon JK, Wadwa RP (2012) Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther 14(Suppl. 1):S51–S58
5. Gerstein HC et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
6. Bonds DE, Miller ME, Bergenstal RM et al (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909
7. Goto A, Arah OA, Goto M et al (2013) Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347:f4533
8. Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119:351–357
9. Robinson RT, Harris ND, Ireland RH et al (2003) Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes 52:1469–1474
10. Tresiba® [prescribing information] (2015) Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf. Accessed 5 July 2017
11. Tresiba® Summary of product characteristics (2015) Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf. Accessed 5 July 2017
12. Ratner RE, Gough SC, Mathieu C et al (2013) Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 15:175–184
13. Wysham C, Bhargava A, Chaykin L et al (2017) Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes; the SWITCH 2 randomized clinical trial. JAMA 318:45–56
14. Lane W, Bailey TS, Gerety G et al (2017) Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes; the SWITCH 1 randomized clinical trial. JAMA 318:33–44
15. Marso S, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723–732
16. Marso SP, McGuire DK, Zinman B et al (2016) Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events)—DEVOTE 1. Am Heart J 179:175–183
17. World Medical Association (2013) Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 310:2191–2194
18. ICH (2001) ICH harmonised tripartite guideline: guideline for good clinical practice. J Postgrad Med 47:199–203
19. Seaquist ER, Anderson J, Childs B et al (2013) Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36:1384–1395
20. Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB (2017) Severe hypoglycemia, cardiovascular outcomes and death—the LEADER experience. Diabetes 66(Suppl. 1):A95 Abstract
21. Hanefeld M, Frier BM, Pistrosch F (2016) Hypoglycemia and cardiovascular risk: is there a major link? Diabetes Care 39(Suppl. 2):S205–S209
22. Wright RJ, Frier BM (2008) Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 24:353–363
23. Frier BM, Schernthaner G, Heller SR (2011) Hypoglycemia and cardiovascular risks. Diabetes Care 34(Suppl. 2):S132–S137
24. Desouza CV, Bolli GB, Fonseca V (2010) Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33:1389–1394
25. Fisher BM, Gillen G, Hepburn DA, Dargie HJ, Frier BM (1990) Cardiac responses to acute insulin-induced hypoglycemia in humans. Am J Phys 258:H1775–H1779
26. Hilsted J, Bonde-Petersen F, Nørgaard MB et al (1984) Haemodynamic changes in insulin-induced hypoglycaemia in normal man. Diabetologia 26:328–332
27. Sommerfield AJ, Wilkinson IB, Webb DJ, Frier BM (2007) Vessel wall stiffness in type 1 diabetes and the central hemodynamic effects of acute hypoglycemia. Am J Physiol Endocrinol Metab 293:E1274–E1279
28. Chow E, Bernjak A, Williams S et al (2014) Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 63:1738–1747
29. Reno CM, Daphna-Iken D, Chen YS, VanderWeele J, Jethi K, Fisher SJ (2013) Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes 62:3570–3581
30. Dandona P, Chaudhuri A, Dhindsa S (2010) Proinflammatory and prothrombotic effects of hypoglycemia. Diabetes Care 33:1686–1687
31. Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM (2010) Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 33:1591–1597
32. Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN (2010) Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 33:1529–1535
33. Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J (1979) Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol 32:434–438
34. Pistrosch F, Hanefeld M (2015) Hypoglycemia and cardiovascular disease: lessons from outcome studies. Curr Diab Rep 15:117
35. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
36. Mellbin LG, Rydén L, Riddle MC et al (2013) Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34:3137–3144
37. Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418
38. Heller SR, Bergenstal RM, White WB et al (2017) Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. Diabetes Obes Metab 19:664–671
39. Cha SA, Yun JS, Lim TS et al (2016) Severe hypoglycemia and cardiovascular or all-cause mortality in patients with type 2 diabetes. Diabetes Metab J 40:202–210
40. Hsu PF, Sung SH, Cheng HM et al (2013) Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care 36:894–900
41. Finfer S, Liu B, Myburgh JA et al (2012) Hypoglycemia and risk of death in critically ill patients. N Engl J Med 367:1108–1118